

## CUMULATIVE INDEX 2001

### Volume 27

---

February	OSTEOPOROSIS, pages 1-268
May	RHEUMATOID ARTHRITIS, pages 269-497
August	ANTIPHOSPHOLIPID (HUGHES) SYNDROME, pages 499-675
November	VASCULITIS, pages 677-926

---

Note: Page numbers of article titles are in **boldface** type

Absorptiometry, in bone density measurement  
dual X-ray, 83, 98-99  
single photon, 82

Acid phosphatase, tartrate-resistant, as bone turnover marker, 53-55

aCL. *See* Anticardiolipin antibody.

Activator protein 1, in rheumatoid arthritis pathogenesis, 360-361

Adhesion molecules  
in T-lymphocyte migration, 318  
inhibitors of, for rheumatoid arthritis, 381, 463-464

Aggrecan  
antibodies to, in rheumatoid arthritis pathogenesis, 342-343  
degradation of, in rheumatoid arthritis, 364

Alcohol use, smoking and, 31

Alendronate, for osteoporosis, 168-169, 178, 202-205  
estrogens with, 152  
glucocorticoid-induced, 246  
in men, 37-38  
pharmacodynamics of, 199-200  
side effects of, 201

Alkaline phosphatase, as marker for bone formation, 50-52

Allen's test, in Buerger's disease, 721-722

Alveolar hemorrhage, in microscopic polyangiitis, 706

Amaurosis fugax, in giant cell arteritis, 781

Amenorrhea, bone status in, 137

Amyloidosis, cerebral, versus vasculitis, 718-719

Amyotrophy, diabetic, 756-757

Anabolic agents, for osteoporosis, 215-233  
glucocorticoid-induced, 246-247

growth hormone, 217-221  
insulin-like growth factor 1, 221-222  
mechanisms of action of, 216-217  
parathyroid hormone, 222-231, 247-248  
safety issues with, 228-229

ANCA. *See* Anti-neutrophil cytoplasmic antibodies.

Androgens. *See also* Testosterone.  
for osteoporosis  
estrogens with, 150-151  
fracture risk and, 28-30

Anemia, hemolytic, in antiphospholipid syndrome, 517-518

Aneurysms, in giant cell arteritis, 681, 683

Angitis  
central nervous system  
histologically defined, 715-717  
isolated, epidemiology of, 734  
leukocytoclastic, cutaneous, 741  
microscopic. *See* Microscopic polyangiitis.

Angiogenesis inhibitors, for rheumatoid arthritis, 383, 463-464

Angiography  
cerebral, in vasculitis, 717-718  
in Takayasu's arteritis, 711, 713  
visceral abdominal, in polyarteritis nodosa, 680-681

Angiopathy, of central nervous system, angiographically defined, 715, 719

Annexins, in coagulation, antiphospholipid antibodies and, 582, 595

Anti-glomerular basement membrane disease, in microscopic polyangiitis, 706

Anti-neutrophil cytoplasmic antibodies atypical, in vasculitis, 805

## Anti-neutrophil cytoplasmic antibodies

(Continued)

- bactericidal/permeability-increasing protein-directed, 803, 805, 808
- disorders related to, 801
- in Churg-Strauss syndrome, 804, 836
- in glomerulonephritis, 708
- in microscopic polyangiitis, 707, 836, 842
- in necrotizing crescentic progressive glomerulonephritis, 836-840, 842, 892
- in rheumatoid arthritis, 801
- in systemic lupus erythematosus, 801
- in vasculitis, 734-736, 887-903
- antibody types and, 835
- antigens involved in, 840-843
- atypical, 805
- cell-mediated immunity in, 894-897
- drug-induced, 853-854
- endothelial cells and, 820-822, 893-894, 897
- etiology of, 897-898
- immune complexes in, 833-834, 838-843
- monocyte interactions in, 889, 894, 896-897
- neutrophil interactions in, 888-893
- pathology of, 887-888
- pathophysiology of, 833-837
- pauci-immune lesions in, 837-838
- serological tests for, 799-813
- types of, 836
- in Wegener's granulomatosis, 702, 836, 839-840, 842-843
- monocyte interactions in, 822-823
- serologic testing and, 800, 804, 808
- myeloperoxidase-directed

  - endothelial effects of, 820-822, 891-892
  - in animal models, 823-825
  - in vasculitis, 801, 804-809
  - unanswered questions concerning, 825-826
  - neutrophil effects of, 817-819, 888-889
  - pathophysiologic relevance of, 836-837

- T cell interactions with, 895
- versus proteinase 3-directed, 888-889
- pathogenicity of, 815-832, 833-848, 887-903
- animal models of, 823-825
- antibody types and, 835
- cell-mediated immunity in, 894-897
- characteristics of, 833-835
- endothelial cells and, 820-822, 893-894, 897
- immune complexes and, 833-834, 838-843
- in vasculitis, 836-843. *See* Anti-neutrophil cytoplasmic antibodies, in vasculitis.

in vitro studies of, 816-823

monocytes and macrophages and,

822-823, 889, 894, 896-897

neutrophils and, 817-820, 888-893

pauci-immune lesions in, 837-838

unanswered questions in, 825-827

perinuclear, in vasculitis, 803-807

proteinase 3-directed

endothelial effects of, 820-822, 891

in vasculitis, 801, 803, 806-809, 825-826

neutrophil effects of, 817-819, 888-889, 892

pathophysiologic relevance of, 836-837

T cell interactions with, 895

versus myeloperoxidase-directed, 888-889

serological tests for, 799-813

antigen capture principle in, 809

availability of, 807

clinical considerations in, 800-801, 807

enzyme immunoassay, 805-807

immunofluorescent, 802-805

immunoprecipitation, 809

in vasculitis, 808-809

results reporting, 807

stains for, 835

Antibody(ies)

CD4 molecule, in rheumatoid arthritis, 447-449

CD5 molecule, in rheumatoid arthritis, 449

endothelial cell, in vasculitis, 834-835, 842, 893-894

etanercept, 434-435

glomerular basement membrane

in microscopic polyangiitis, 707

in vasculitis, 834-835

hepatitis C virus, 709

in rheumatoid arthritis pathogenesis, 339-343

infliximab, 430-431

interleukin-2 receptor, in rheumatoid arthritis, 449-450

monoclonal. *See* Monoclonal antibodies. neutrophil cytoplasmic. *See* Anti-neutrophil cytoplasmic antibodies.

normal development and selection of, 337-339

structure of, 337

Anticardiolipin antibody

in antiphospholipid syndrome, 501

heart disease and, 512-514, 665

prognosis and, 661-662

stroke and, 508

in syphilis, 551-552

in transplantation

bone marrow, 624-625

heart, 621-622

- kidney, 614–618
- tests for, 532–536
- Anticoagulants, for antiphospholipid syndrome
  - acute, 633–634
  - catastrophic, 634–635
  - chronic, 635–640
  - prognosis in, 666
- Antigen(s), in vasculitis
  - anti-neutrophil cytoplasmic antibodies directed to, 840–843
  - bacterial, in 842–843
  - endothelial cell, 842
- Antigen-antibody (immune) complexes, in vasculitis, anti-neutrophil cytoplasmic antibodies and, 833–834, 838–843
- Antiphospholipid antibodies. *See also* Antiphospholipid (Hughes) syndrome; specific antibodies.
  - atherosclerosis and, 603–610
  - coagulation cascade and, 573–586
  - endothelial interactions with, 587–602
  - in syphilis, 551–552
  - origin of, 551–563
    - animal studies of, 553–558
    - $\beta_2$ -glycoprotein cofactor and, 554–556, 558–559
    - historical background of, 551–553
    - molecular mimicry and, 556–559
    - peptide immunization, 555–559
  - tests for, 501, 525–549, 583
    - current status of, 525–528
    - immune detection type, 532–536
    - in cerebrovascular monitoring, 539–540
    - in kidney monitoring, 540
    - in pregnancy, 538–539
    - indirect, 536–538
    - multiple, 532, 535
    - populations targeted for, 529–531
    - prognosis and, 662–664
    - solid-phase immunoassays, 553
    - transplantation and, 612–613
    - transplantation and, 516, 611–631
- Antiphospholipid (Hughes) syndrome. *See also* Antiphospholipid antibodies.
  - asymptomatic, prognosis for, 661–662
  - catastrophic, 634–635, 666
  - chronic, treatment of, 635–640
  - classification criteria for, 499–505
    - aims of, 500, 502
    - clinical, 501
    - evaluation of, 503
    - for diagnosis, 504
    - laboratory, 501
    - limitations of, 500, 502
    - versus noncriteria features, 502–503
    - clinical features of, 507–524
      - cardiac, 512–514, 665
      - central nervous system, 507–511, 539–540, 665
  - cutaneous, 511–512
  - hematologic, 517–518, 639, 664
  - kidney, 514–516, 540, 665
  - obstetric. *See* Pregnancy, in antiphospholipid syndrome.
  - prognosis and, 664–666
  - pulmonary, 516–517, 633–634, 664–665
  - diagnosis of
    - classification criteria and, 504
    - definitive, 530
  - genetics of, 565–572
  - in pregnancy. *See* Pregnancy, in antiphospholipid syndrome.
  - in transplantation. *See* Transplantation.
  - long-term follow-up in, 662–664
  - prognosis in, 661–669
    - in asymptomatic state, 661–662
    - in pregnancy, 664
    - in systemic lupus erythematosus, 662
    - in thrombocytopenia, 664
    - long-term follow-up in, 662–664
    - versus clinical manifestations, 664–666
  - treatment of, 633–642
    - acute, 633–634
    - catastrophic, 634–635
    - chronic, 635–640
    - in pregnancy, 649–654
- Anxiety, in osteoporosis, 256–257
- Aorta
  - giant cell arteritis of, 681, 683
  - Takayasu's arteritis of
    - carotid artery bypass in, 714
    - epidemiology of, 733
- Apoptosis
  - in antiphospholipid antibody induction, 596–597, 626–627
  - inhibition of, in rheumatoid arthritis, 465–466
  - of neutrophils, in vasculitis, 892–893
- Arterial thrombosis, in antiphospholipid syndrome, treatment of, 634
- Arteritis
  - giant cell. *See* Giant cell (temporal) arteritis.
  - in polyarteritis nodosa. *See* Polyarteritis nodosa.
  - Takayasu's. *See* Takayasu's arteritis.
  - temporal. *See* Giant cell (temporal) arteritis.
- Arthritis
  - in drug-induced vasculitis, 854
  - osteoporosis and, estrogen effects on, 145–146, 153–154
  - rheumatoid. *See* Rheumatoid arthritis.
- Arthroscopy, for rheumatoid arthritis, synovial membrane characterization in, 374–376
- Aspirin
  - for antiphospholipid syndrome
    - chronic, 638

Aspirin (*Continued*)  
 in pregnancy, 649–652, 654  
 for rheumatoid arthritis, 390, 393

Atherosclerosis  
 antiphospholipid antibodies and, 603–610  
 clinical implications of, 607  
 immune system involvement in, 605–607  
 in antiphospholipid syndrome, 604–605  
 in systemic lupus erythematosus, 603–604  
 in rheumatoid arthritis, 287–288  
 corticosteroid-induced, 398

Athletes, bone mass in, 133

Atovaquone, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878

Atrophie blanche, in polyarteritis nodosa, 681–682

Autoimmune disorders  
 ANCA-associated, 897–898  
 etanercept-induced, 434–435  
 infliximab-induced, 430–431

Azathioprine  
 for Behcet's disease, 772  
 for Henoch-Schönlein purpura, 689  
 for rheumatoid arthritis, carcinogenic effects of, 289–290  
 for Wegener's granulomatosis, 872

B lymphocytes, in rheumatoid arthritis  
 pathogenesis, 335–353  
 antibodies in, 339–343  
 historical overview of, 335–337  
 in synovial membrane infiltrates, 343–345  
 TdT protein abnormalities in, 345–346  
 treatment implications of, 346, 465  
 versus normal B-lymphocyte development and selection, 337–339

B7 molecule, inhibitors of, for rheumatoid arthritis, 452–453

Bacterial antigens, in vasculitis, in 842–843

Bactericidal/permeability-increasing protein, anti-neutrophil cytoplasmic antibodies directed to, 803, 805, 808

Behcet's disease  
 bruit in, 710  
 central nervous system involvement in, 719–721  
 erythema nodosum in, 719  
 ocular manifestations of, 770–772  
 retinal vasculitis in, 771–772  
 thrombophlebitis in, 719  
 uveitis in, 764  
 vasculitis in, 743

Biochemical markers, of bone turnover. *See* Bone, turnover of, biochemical markers for.

Biologic agents  
 for rheumatoid arthritis, 445–491. *See also* specific agents.  
 methotrexate with, 422  
 targets for  
 adhesion molecules, 381, 463–464  
 angiogenesis, 383, 463–464  
 apoptosis, 465–466  
 B lymphocytes, 465  
 CD antigen, 447–449  
 complement, 465  
 costimulatory molecules, 320–322, 452–453  
 cytokines, 454–464  
 gene therapy, 467  
 interferons, 458–459  
 interleukin-1 receptor, 456–457  
 interleukins, 454, 457–462  
 major histocompatibility complex, 453–454  
 metalloproteinases, 363–364, 466–467  
 mitogen-activated protein kinases, 361, 438, 462–463  
 nuclear factor- $\kappa$ B, 362–363, 383, 463  
 T-cell receptor, 450–451  
 T lymphocytes, 446–454

vasculitis due to, 852

Biopsy  
 brain, in vasculitis, 717  
 gastrocnemius muscle, in polyarteritis nodosa, 680  
 in Churg-Strauss syndrome, 705  
 in drug-induced vasculitis, 855  
 kidney, in idiopathic rapidly progressive glomerulonephritis, 708  
 muscle, in vasculitic neuropathy, 754, 756  
 nerve, in vasculitic neuropathy, 754, 756  
 skin, in Henoch-Schönlein purpura, 689–692  
 sural nerve  
 in Churg-Strauss syndrome, 705  
 in polyarteritis nodosa, 680  
 synovial, in rheumatoid arthritis, 374–376  
 temporal artery, 683–687

Bisphosphonates  
 clinical uses of, 201  
 for metastatic bone disease, 68, 70  
 for osteoporosis, 168–169, 178, 197–214.  
*See also* specific drugs.  
 approved agents for, 201–206  
 chemistry of, 197–198  
 comparison of, 207–208  
 developmental, 207  
 estrogens with, 152

glucocorticoid-induced, 244–246  
in men, 37–38  
in rheumatoid arthritis, 293  
mechanisms of action of, 198–199  
nonapproved agents for, 206–207  
pharmacodynamics of, 199–200  
side effects of, 200–201

Blood-nerve barrier, 752

Blood pressure, measurement of, in giant cell arteritis, 683

Body mass index, osteoporosis risk and, 31

Bone  
formation of  
hormones in, 28  
over life cycle, 131–132  
loss of, in rheumatoid arthritis, 292–293, 295, 398  
metastasis to, bone turnover markers in, 65–70  
necrosis of, glucocorticoid-induced, 239–240  
remodeling of, over life cycle, 131–132  
remodeling transient of, 102–103  
resorption of, glucocorticoids in, 237–238  
strength of, in men versus women, 25–27  
turnover of  
biochemical markers for, 49–80, 166  
alkaline phosphatase, 50–52  
bone sialoprotein, 53–54  
calcitonin effects on, 191  
collagen propeptides, 51–53  
formation, 50–53  
hydroxylysine, 54–56  
hydroxyproline, 54–56  
hydroxypyridinium cross-links, 54, 56–57  
in bone disease treatment monitoring, 68, 70  
in breast cancer, 67  
in glucocorticoid-induced bone disease, 70–72  
in hyperparathyroidism, 62–64  
in malignant bone disease, 65, 67  
in multiple myeloma, 67–69  
in osteoporosis, 57–62  
in Paget's disease, 63  
in rheumatic disease, 72  
osteocalcin, 51–52  
resorption, 53–57  
tartrate-resistant acid phosphatase, 53–55  
estrogens in, 143–144

Bone marrow transplantation, antiphospholipid antibodies and, 623–626

Bone mass, peak, 34  
calcium importance in, 112  
in men versus women, 26

Bone mineral density  
calcitonin effects on, 188–189

calcium supplementation effects on, versus life cycle, 112–117  
exercise effects on, versus life cycle, 135–136  
genetic factors in, 10  
glucocorticoid effects on, 240–241  
growth hormone effects on, 218–221  
in children, 133–135  
in men versus women, 26  
in osteoporosis  
criteria for, 1–2  
preventive strategies based on, 15  
measurement of. *See* Densitometry  
versus fracture risk, 2–3  
vitamin D effects on, 122

Bone pain, calcitonin effects on, 192–193

Bone sialoprotein, as marker for bone resorption, 53–54

Brain, vasculitis of, 715–719  
biopsy in, 717  
versus amyloidosis, 718–719  
versus mass, 716

Breast cancer, bone metastasis in, bone turnover markers in, 67

Bruit, in Takayasu's arteritis, 710–711

Buerger's disease  
causes of, 722  
digital ischemia in, 721  
pulse loss in, 711  
thrombophlebitis in, 721  
treatment of, 722–723  
ulcers in, 721–722

C-reactive protein, in Takayasu's arteritis, 711

Calcitonin, for osteoporosis, 169, 178, 187–196  
analgesic effects of, 192–193  
glucocorticoid-induced, 244, 879  
in combination therapy, 194  
in men, 38  
injectable, 188  
nasal, 188–193  
physiology of, 187  
preventive role of, 189  
resistance to, 193  
side effects of, 193  
steroid-induced, 192  
structure of, 187

Calcium  
metabolism of, glucocorticoid effects on, 239  
osteoporosis and, 104–117  
absorption of, 104–105  
balance of, factors affecting, 106–107  
body distribution of, 104  
dietary guidelines for, 107–108  
food sources of, 107

Calcium (*Continued*)  
 in elderly persons, 116–117  
 in lactation, 113–114  
 in menopause, 114–116  
 in pregnancy, 113–114  
 in rheumatoid arthritis, 293  
 metabolism of, 104  
 peak bone mineral density achievement, 112  
 studies of, 109–111  
 supplementation with, 109, 166–167  
   in calcitonin therapy, 193  
   in glucocorticoid therapy, 242–243  
 in men, 37  
 studies of, 109–111  
 types of, 109  
 versus life cycle, 112–117  
 urinary levels of, 106  
 versus life cycle, 112–117

Cancer  
 breast, bone metastasis in, bone turnover markers in, 67  
 in rheumatoid arthritis, 288–290, 294  
 infliximab-induced, 431  
 vasculitis related to, 743

Carbon dioxide, diffusion capacity of, in microscopic polyangiitis, 706

Cardiolipin, antibody to. *See* Anticardiolipin antibody.

Cardiomyopathy, in Takayasu's arteritis, 713

Cardiovascular disease, in rheumatoid arthritis, 285–288, 294

Carotid artery bypass, in Takayasu's arteritis, 714

Cartilage, antibodies to, in rheumatoid arthritis pathogenesis, 342–343

Cathepsins, in rheumatoid arthritis pathogenesis, 364–366

CD4 molecule, antibodies to, in rheumatoid arthritis, 447–449

CD5 molecule, antibodies to, in rheumatoid arthritis, 449

CD28 molecule, inhibitors of, for rheumatoid arthritis, 452–453

CD40 molecule  
 in rheumatoid arthritis pathogenesis, 321–322  
 in vasculitis pathogenesis, 894  
 inhibitors of, for rheumatoid arthritis, 452–453

CD44 molecule, inhibitors of, for rheumatoid arthritis, 463–464

CD80 molecule, in rheumatoid arthritis pathogenesis, 320–322

CD86 molecule, in rheumatoid arthritis pathogenesis, 320–322

CD154 molecule, inhibitors of, for rheumatoid arthritis, 452–453

CDP 870 anti-tumor necrosis factor fragment, for rheumatoid arthritis, 436

Central nervous system  
 antiphospholipid syndrome manifestations in, 507–511, 539–540, 665

Behcet's disease of, 719–721

isolated angiitis of, epidemiology of, 734

vasculitis of, 715–719

Chemokines and chemokine receptors  
 in T-lymphocyte migration, 318–319

inhibitors of, for rheumatoid arthritis, 464

Chest radiography, in Wegener's granulomatosis, 695

Chlorambucil  
 for Behcet's disease, 771  
 for Wegener's granulomatosis, 876

Chloroquine, for rheumatoid arthritis, 408

Cholecalciferol (vitamin D<sub>3</sub>), osteoporosis and  
 metabolism of, 117–118

supplementation with, 123–124

Churg-Strauss syndrome  
 anti-neutrophil cytoplasmic antibodies in, 800, 804, 836, 888–889

biopsy in, 705

drug-induced, 852

eosinophil count in, 704

epidemiology of, 734, 737

immune complexes in, 839

kidney involvement in, 704–705

myocardial vasculitis in, 703

ocular manifestations of, 769–770

peripheral neuropathy in, 703

rheumatoid nodules in, 702–703

stages of, 702

treatment of, 704

versus hypereosinophil syndrome, 704

versus Wegener's granulomatosis, 702–703

Claudication, jaw, in giant cell arteritis, 684–685

Clodronate, for osteoporosis, 199, 206–207

Coagulation cascade, antiphospholipid antibodies and, 573–586

activated protein C regulation, 578–580

coagulation factor activation, 577–578

detection, 583

$\beta_2$ -glycoprotein. *See*  $\beta_2$ -Glycoprotein.

inhibition, 580

membrane dynamics, 576–577, 580–582

platelets, 576

surface dynamics, 574–578, 580, 583

Cocaine, vasculitis due to, 852–853

Cogan's syndrome, 714–715  
 bruit in, 710–711  
 ocular manifestations of, 775

Cognitive dysfunction, in antiphospholipid syndrome, 509

Collagen  
 antibodies to, in rheumatoid arthritis pathogenesis, 342

receptors for, in rheumatoid arthritis  
pathogenesis, 322–323

**Collagen propeptides, type I, as bone turnover marker, 51–53**

**Collagenases, in rheumatoid arthritis pathogenesis, 363**

**Complement**  
imbalance of, in cryoglobulinemic vasculitis, 709  
inhibitors of, for rheumatoid arthritis, 465

**Computed tomography, quantitative, in bone density measurement, 83, 85, 88**

**Cornea**  
inflammation of. *See* Keratitis.  
ulcers of, in giant cell arteritis, 792

**Coronary artery disease, in antiphospholipid syndrome, 513–514**

**Corticosteroids**  
for antiphospholipid syndrome, 650  
for ocular manifestations, of vasculitis  
Behcet's disease, 772  
Churg-Strauss syndrome, 769–770  
Cogan's syndrome, 775  
giant cell arteritis, 777  
keratitis, 764  
optic neuritis, 766  
optic neuropathy, 766  
polyarteritis nodosa, 774  
scleritis, 763  
Takayasu's arteritis, 775  
uveitis, 764–765

for polymyalgia rheumatica, 688–689

for rheumatoid arthritis, 389–403  
adverse effects of, 395–398  
cardiovascular, 287  
gastrointestinal, 296  
osteoporosis, 292–293, 295

disease progression and, 394–395  
early, 407–410  
evidence-based treatment strategy for, 398–400  
in combinations, 422–423  
radiologic progression and, 393–394  
symptom relief and, 389–392

for vasculitis  
Behcet's disease, 772  
Churg-Strauss syndrome, 769–770  
Cogan's syndrome, 775  
drug-induced, 857  
giant cell arteritis, 683–684, 777  
Henoch-Schönlein purpura, 689  
neuropathic, 756, 758  
polyarteritis nodosa, 678, 774  
Takayasu's arteritis, 714, 775  
Wegener's granulomatosis, 698–699, 864–865  
methotrexate with, 869–871  
ocular manifestations, 769

osteoporosis due to, 235–253

assessment of, 240–241  
bone resorption in, 237–238  
bone turnover markers in, 70–72  
calcitonin for, 192  
clinical features of, 235–236  
epidemiology of, 236–237  
estrogen effects on, 150  
hormonal factors in, 238–239  
mineral metabolic abnormalities in, 239

muscular effects of, 240  
osteonecrosis in, 239–240  
parathyroid hormone in, 226–228, 247–248

pathophysiology of, 237–240  
prevention and treatment of, 241–248, 879

**Cortisol, in osteoporosis programming, 12**

**Cortisone, for rheumatoid arthritis, 390**

**Costimulatory molecules**  
in rheumatoid arthritis pathogenesis, 320–322

inhibitors of, for rheumatoid arthritis, 452–453

**Cranial neuropathy, in vasculitis, 766–767**

**Crossmatching, with fluorescence-activated cell sorter, antiphospholipid antibody impact on, 622–623**

**Cryoglobulinemic vasculitis, 708–710**  
epidemiology of, 741  
immune complexes in, 834  
pearls and myths about, 708–710

**Culture, in rheumatoid arthritis, 376**

**Cushing's disease, osteopenia in, bone turnover markers in, 70–72**

**Cyclophosphamide**  
for Behcet's disease, 772  
for polyarteritis nodosa, 678  
for vasculitic neuropathy, 756, 758  
for Wegener's granulomatosis, 695–697, 769, 865–868, 878–879

**Cyclosporine**  
for Behcet's disease, 772  
for rheumatoid arthritis, 408–410, 420  
for Wegener's granulomatosis, 876  
neurotoxicity of, 720

**Cysteine proteases, in rheumatoid arthritis pathogenesis, 364–366**

**Cystitis, cyclophosphamide-induced, 878–879**

**Cytokines**  
culture of, in rheumatoid arthritis, 376  
in endothelial damage, in vasculitis, 895–896  
in rheumatoid arthritis pathogenesis, 319–320, 326–327, 378–383  
inhibitors of, for rheumatoid arthritis, 454–464

**Cytomegalovirus infections, antiphospholipid antibody induction in, 555–558**

Cytotoxic T lymphocyte-associated clone 4, inhibitors of, for rheumatoid arthritis, 453

Dalteparin, for antiphospholipid syndrome, in pregnancy, 654

Dapsone, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878

D2E7 monoclonal antibody, in rheumatoid arthritis treatment, 435-436

7-Dehydrocholesterol, as vitamin D precursor, 117-118

Dehydroepiandrosterone, deficiency of, osteoporosis in, 30

Dementia, in antiphospholipid syndrome, 509

Densitometry, 81-100, 166  
central versus peripheral, 95-96  
in children, 99, 133-135  
in fracture risk assessment, 94-95  
in glucocorticoid-induced osteoporosis, 240-241  
in skeletal change monitoring, 95  
of hip, 98  
peripheral versus central, 95-96  
results of, versus normative data, 92-94  
special scans in, 96-99  
techniques for, 81-91  
comparison of, 91-92  
computed tomography, 83, 85, 88  
dual energy, 82-84, 86-87, 98-99  
radiation dose for, 90-91  
single energy, 82  
terminology of, 81-82  
ultrasonography, 88-90  
uses of, 91-99  
vertebral morphometry scans in, 97

Dental health, estrogen effects on, 149

Depression, in osteoporosis, 258-259

Dermatomyositis, vasculitis in, 743

Diabetes mellitus, amyotrophy in, 756-757

Dialysis, in Wegener's granulomatosis, 882

Digital ischemia, in Buerger's disease, 721

1,25-Dihydroxyvitamin D (calcitriol),  
osteoporosis and  
deficiency of, 121  
metabolism of, 117-119  
supplementation with, 122, 124-125

Diplopia, in giant cell arteritis, 789-790

Direct immunofluorescence test, in  
Henoch-Schönlein purpura, 689-692

Disease-modifying antirheumatic drugs, for rheumatoid arthritis, combination, 415-426  
biologic agents in, 422  
in early disease, 417-419  
in methotrexate failure, 419-420

indications for, 417  
nonconventional, 422-423  
patient selection for, 423  
triple, 420-421

Disintegrins, in rheumatoid arthritis  
pathogenesis, 364

DMARDs. *See* Disease-modifying  
antirheumatic drugs

dnaj heat shock protein, antibodies to, in  
rheumatoid arthritis, 341

Doxycycline, for rheumatoid arthritis, 423

Drugs  
abuse of, vasculitis due to, 852-853  
osteoporosis due to, in men, 32  
vasculitis due to. *See* Vasculitis, drug-induced.

Dual energy densitometry, 82-84, 86-87, 98-99

Dyslipidemia, in rheumatoid arthritis, 285-288

Ear complications, in Wegener's  
granulomatosis, 879-880

Eicosanoid metabolism, endothelial,  
antiphospholipid antibodies and, 595-596

Elderly persons  
calcium supplementation for, 116-117  
exercise for, 137-138

Electromyography, in Churg-Strauss  
syndrome, 705

Embolism, pulmonary, in antiphospholipid  
syndrome, 516, 633-634, 664-665

Endosomes, late, endothelial,  
antiphospholipid antibody interactions  
with, 597

Endothelial cells  
anti-neutrophil cytoplasmic antibodies  
and, 820-822, 893-894, 897  
antibodies to, in vasculitis, 834-835, 842,  
893-894

Endothelins, antiphospholipid antibody  
interactions with, 596

Endothelium, antiphospholipid antibody  
interactions with, 587-602  
annexin V in, 595  
apoptosis, 596-597  
eicosanoid metabolism and, 595-596  
 $\beta$ -glycoprotein cofactor in, 589-591  
late endosome, 597  
mechanisms of, 593-594  
proadhesive and proinflammatory phe-  
notype induction in, 591-593  
procoagulant phenotype and, 594-595  
versus anatomic district, 597-598  
vessel tone regulation and, 596

Enoxaparin, for antiphospholipid  
syndrome, in pregnancy, 654

Environmental factors  
 in giant cell arteritis, 731  
 in Henoch-Schönlein purpura, 740  
 in osteoporosis, 10–12  
 in rheumatoid arthritis, 276–277

Enzyme immunoassays, for anti-neutrophil cytoplasmic antibodies, 805–807

Enzyme-linked immunosorbent assay, for antiphospholipid antibodies, 533, 553

Eosinophilia  
 in Churg-Strauss syndrome, 702, 704  
 in drug-induced vasculitis, 855

Episcleritis, in vasculitis, 761–763

Ergocalciferol (vitamin D<sub>3</sub>), osteoporosis  
 and  
 metabolism of, 117–118  
 supplementation with, 123–124

Erythema nodosum, in Behcet's disease, 719

Erythrocyte sedimentation rate  
 in giant cell arteritis, 685–686  
 in Takayasu's arteritis, 711

*Escherichia coli* heat shock protein, antibodies to, in rheumatoid arthritis, 341

Estrogens  
 for osteoporosis, 143–162, 167–168  
 androgens with, 150–151  
 arthritis and, 145–146, 153–154  
 benefits of, 152–155  
 dental aspects of, 149  
 disadvantages of, 153  
 exercise with, 152  
 fracture risk and, 28–30, 144–145  
 glucocorticoid-induced, 243–244  
 indications for, 147–148  
 initiation of, 148–149  
 low-dose, 151  
 nutritional supplements with, 152  
 physiology of, 143–144  
 products for, 146–147  
 progesterone with, 150  
 selective estrogen receptor modulators with, 151–152  
 rheumatoid arthritis and, 277, 287–288

Etanercept  
 antibodies and autoantibodies to, 434–435  
 for rheumatoid arthritis, 410, 422, 432–435  
 for Wegener's granulomatosis, 877

Ethnic factors, in osteoporosis, 9–10  
 in men, 21–22

Etidronate, for osteoporosis, 201–202, 206  
 glucocorticoid-induced, 245–246  
 in men, 37–38  
 mechanism of action, 198–199  
 pharmacodynamics of, 199–200  
 side effects of, 200

Evans' syndrome, 517

Exercise, for osteoporosis prevention and treatment, 31–32, 131–141

amenorrhea and, 137  
 bone physiology and, 131–135  
 estrogens with, 152  
 goals of, 138–139  
 gymnastics and, 137  
 in older people, 137–138  
 swimming, 137  
 versus life cycle, 135–136

Extracellular matrix proteins, in rheumatoid arthritis pathogenesis, 322–323, 363–366

Extracellular signal-regulated kinase, in rheumatoid arthritis pathogenesis, 361

Eye, vasculitis manifestations in. *See also* Ocular manifestations, of vasculitis.

Factor V Leiden, antiphospholipid syndrome and, 570

Falls  
 in men versus women, 27  
 prevention of, 15, 36–37, 180  
 exercise in, 137–138  
 risk factors for, in men, 33

Fever, in giant cell arteritis, 685

Fibronectin receptors, in rheumatoid arthritis pathogenesis, 322–323

FK506 (tacrolimus)  
 for Wegener's granulomatosis, 876  
 neurotoxicity of, 720

Fluorescence-activated cell sorter, for crossmatching, antiphospholipid antibody impact on, 622–623

Fluoride supplementation, in osteoporosis, 38, 246–247

Forearm  
 densitometry of, quantitative computed tomography in, 88  
 fractures of, in osteoporosis  
 epidemiology of, 6, 25  
 morbidity in, 14

Fractures  
 in osteoporosis. *See also specific bones.*  
 bone density and, 2–3  
 calcitonin effects on, 188–191  
 clustering of, 6–7  
 consequences of, 163–164  
 epidemiology of, 2–7, 22–25  
 geographical factors in, 9–10  
 morbidity in, 13–14  
 mortality in, 12–13  
 occurrence of, 3–7  
 prediction of  
   bone turnover markers in, 61–62  
   densitometry in, 94–95  
 prevention of, 14–15  
 risk factors for

Fractures (Continued)  
 estrogen deficiency, 144-145  
 in men, 27-33  
 time trends in, 7-9  
 treatment effects on, 177-180  
 in rheumatoid arthritis, 292-293, 295

Free radicals, in endothelial damage, 891

Gangrene, in antiphospholipid syndrome, 512, 665-666

Gastrocnemius muscle, biopsy of, in polyarteritis nodosa, 680

Gastrointestinal disease, in rheumatoid arthritis, 293, 295-296

Gelatinases, in rheumatoid arthritis pathogenesis, 363-364

Gene therapy, for rheumatoid arthritis, 467

Genetic factors  
 in antiphospholipid syndrome, 565-572  
 $\beta$ -glycoprotein, 565-568  
 human leukocyte antigen genotypes and, 568-569  
 risk factors and, 568-570  
 variance in, 569-570

in giant cell arteritis, 730-731

in Kawasaki disease, 738-739

in osteoporosis, 10

in rheumatoid arthritis, 275-276, 305-315  
 in Takayasu's arteritis, 732-733

Giant cell (temporal) arteritis  
 aortic, 681, 683  
 blood pressure measurement in, 683  
 bruit in, 710  
 environmental factors in, 731  
 epidemiology of, 730-732  
 genetic factors in, 730-731  
 pulse loss in, 711  
 treatment of, 687-688  
 vessels affected in, 681, 683  
 visual manifestations of, 775-777, 781-797  
 corneal ulceration, 792  
 diplopia, 789-790  
 hallucinations, 789  
 ischemic optic neuropathy, 776, 784-787  
 ocular hypotony, 791  
 ocular ischemic syndrome, 790-791  
 pupillary disturbances, 790  
 retinal artery occlusion, 782-784  
 visual field defects, 787-789  
 visual loss, 781-782

Glomerular basement membrane, antibodies to  
 in microscopic polyangiitis, 707  
 in vasculitis, 834-835

Glomerulonephritis  
 idiopathic rapidly progressive, 707-708, 896-897

necrotizing crescentic progressive, anti-neutrophil cytoplasmic antibodies in, 836-840, 842, 892

pauci-immune, 837-838

Glucocorticoids. *See* Corticosteroids.

$\beta$ -Glycoprotein  
 antibodies to  
 induction of, 554-556, 558-559  
 tests for, 532-534, 537

antiphospholipid antibody interactions with  
 cofactor function of, 589  
 in endothelium, 589-591

deficiency of, genetics of, 567-568  
 in antiphospholipid syndrome  
 atherosclerosis and, 604-605  
 genetics of, 565-568  
 polymorphisms of, 565-567  
 in coagulation, 582-583

Gold salts, for rheumatoid arthritis, versus prednisolone, 391

Granulocyte colony-stimulating factor, in neutropenia, in Wegener's granulomatosis, 879

Granulomatosis, Wegener's. *See* Wegener's granulomatosis.

Growth hormone  
 deficiency of, osteoporosis in, in men, 32  
 for osteoporosis treatment, 217-222

Gymnasts, bone status of, 137

Hallucinations, visual, in giant cell arteritis, 789

Headache  
 in giant cell arteritis, 685  
 migraine, anticardiolipin antibodies and, 508-509

Hearing loss, in antiphospholipid syndrome, 511

Heart  
 antiphospholipid syndrome manifestations in, 512-514, 665  
 transplantation of, antiphospholipid antibodies and, 620-621

Heat shock protein, antibodies to, in rheumatoid arthritis, 341

Hematuria, in Wegener's granulomatosis, 694-695

Hemolytic anemia, in antiphospholipid syndrome, 517-518

Hemorrhage  
 alveolar, in antiphospholipid syndrome, 517  
 pulmonary, in microscopic polyangiitis, 706

splinter, in Buerger's disease, 722

subungual, in antiphospholipid syndrome, 512

Henoch-Schönlein purpura  
epidemiology of, 739–741  
immune complexes in, 834  
immunoglobulin A deposition in, 694  
immunoglobulin A paraproteinemia in, 692–693  
intussusceptions in, 693  
prolonged standing in, 693  
renal involvement in, 693  
skin biopsy in, 689–692  
treatment of, 689  
versus microscopic polyangiitis, 692

Heparin, for antiphospholipid syndrome  
acute, 633–634  
chronic, 639  
in pregnancy, 651–654

Hepatitis B, vasculitic neuropathy in, 757–758

Hepatitis C  
antibodies in, 709  
antiphospholipid antibody induction in, 559, 616  
vasculitic neuropathy in, 757–758

Hip  
densitometry of, 98  
fractures of, in osteoporosis  
calcium absorption and, 104–105  
epidemiology of, 4–5, 7–9, 22–24  
ethnic factors in, 9–10  
morbidity in, 14  
mortality in, 13  
prediction of, 89–90, 94  
risk of, in estrogen deficiency, 144–145  
treatment effects on, 177–180  
with other fractures, 6–7

Hormones. *See also specific hormones.*  
disorders of, osteoporosis due to, in men, 32–33  
in osteoporosis  
fracture risk and, 27–31  
in early programming, 11–12

Horner's syndrome, in giant cell arteritis, 790

*hprt* gene mutations, in rheumatoid arthritis, 360

Hughes syndrome. *See* Antiphospholipid (Hughes) syndrome.

Human leukocyte antigens  
antiphospholipid antibodies and, 568–569  
in Henoch-Schönlein purpura, 740  
in rheumatoid arthritis susceptibility, 305–315  
in Takayasu's arteritis, 732–733  
in vasculitis, 735

Humeral fractures, in osteoporosis, epidemiology of, 6

Hyaluronan receptor, inhibitors of, for rheumatoid arthritis, 463–464

Hydroxychloroquine  
for antiphospholipid syndrome, 639–640  
for rheumatoid arthritis, 407, 410  
in combinations, 418, 420–421

Hydroxylysine, as bone turnover marker, 54–56

Hydroxyproline, as bone turnover marker, 54–56

Hydroxypyridinium cross-links, as bone turnover markers, 54, 56–57

Hypercalcioria, osteoporosis in, 106

Hypereosinophilic syndrome, versus Churg-Strauss syndrome, 704

Hyperparathyroidism  
bone turnover markers in, 62–64  
secondary, senile osteoporosis in, 123

Hypersensitivity vasculitis. *See also Vasculitis, drug-induced.*  
epidemiology of, 741

Hypertension, in antiphospholipid syndrome  
pulmonary, 516–517, 530–531, 664–665  
systemic, 514–515

Hypogonadism, osteoporosis risk in, 28–30

Hypopyon, in Behcet's disease, 771

Hypotony, ocular, in giant cell arteritis, 791

Idiopathic rapidly progressive glomerulonephritis, 707–708, 896–897

Immobilization, osteoporosis risk in, 31–32, 132

Immune complexes, in vasculitis, anti-neutrophil cytoplasmic antibodies and, 833–834, 838–843

Immune globulin  
for antiphospholipid syndrome, 635  
in pregnancy, 653  
intravenous, for Wegener's granulomatosis, 875–876

Immune system, in atherosclerosis development, 605–607

Immunodeficiency, in rheumatoid arthritis  
infections in, 290–292, 295  
treatment-related, 288–290

Immunofluorescent test, for anti-neutrophil cytoplasmic antibodies, 802–805

Immunoglobulin(s)  
Fc portion of, antibodies to. *See* Rheumatoid factor.  
in rheumatoid arthritis pathogenesis, 345–346, 465  
normal development and selection of, 337–339  
structure of, 337

Immunoglobulin A, in Henoch-Schönlein purpura, 692–694

Immunosuppressive therapy  
for antiphospholipid syndrome, in pregnancy, 653

Immunosuppressive therapy (*Continued*)  
 for Churg-Strauss syndrome, 704  
 for drug-induced vasculitis, 857  
 for Henoch-Schönlein purpura, 689  
 for scleritis, in vasculitis, 763  
 for vasculitic neuropathy, 758  
 for Wegener's granulomatosis, 769  
 Indomethacin, for scleritis, in vasculitis, 763  
**Infections**  
 antiphospholipid antibody induction in, 555-559  
 in rheumatoid arthritis, 276-277, 290-292, 295, 397  
 etanercept-related, 434  
 infliximab-related, 430  
 tumor necrosis factor- $\alpha$  blocker-related, 438  
 vasculitis related to, 735, 743, 842-843  
 Henoch-Schönlein, 739-740  
 Kawasaki disease, 739  
 Wegener's granulomatosis, 700-702  
**Inflammation**  
 in atherosclerosis development, 605-607  
 in rheumatoid arthritis, pathogenesis of.  
*See* Rheumatoid arthritis, pathogenesis of.  
 Infliximab, for rheumatoid arthritis, 410, 428-432  
 antibodies and autoantibodies to, 430-431  
 methotrexate with, 422  
 Insulin-like growth factor 1  
 deficiency of, osteoporosis in, in men, 32  
 for osteoporosis prevention and treatment, 221-222  
 Integrins, inhibition of, in rheumatoid arthritis, 464  
 Intercellular adhesion molecule-1, inhibitors of, for rheumatoid arthritis, 381, 463  
**Interferon(s)**  
 for rheumatoid arthritis treatment, 458-459  
 in rheumatoid arthritis pathogenesis, 319-320, 326-327, 378-383  
 vasculitis due to, 852  
**Interleukin(s)**  
 in rheumatoid arthritis pathogenesis, 319-320, 326-327, 378-383  
 inhibitors of, for rheumatoid arthritis, 454, 462  
 Interleukin-1 receptor antagonists, in rheumatoid arthritis, 456-457  
 Interleukin-2 receptor, antibodies to, in rheumatoid arthritis, 449-450  
 Interleukin-4, for rheumatoid arthritis, 461  
 Interleukin-6, inhibitors of, for rheumatoid arthritis, 459  
 Interleukin-8  
 in neutrophil sequestration, 890-891  
 inhibitors of, for rheumatoid arthritis, 464  
 Interleukin-10, for rheumatoid arthritis, 379, 459-461  
 Interleukin-11, inhibitors of, for rheumatoid arthritis, 462  
 Interstitial keratitis, in vasculitis, 763-764  
 in Cogan's syndrome, 775  
 Intussusception, in Henoch-Schönlein purpura, 693  
 Ischemia, of optic nerve, in giant cell arteritis, 776, 784-787  
  
**Jaw claudication**, in giant cell arteritis, 684-685  
**Jun N-terminal kinase**, in rheumatoid arthritis pathogenesis, 361  
  
**Kawasaki disease**, epidemiology of, 738-739  
**Keratitis**  
*in* Cogan's syndrome, 714-715, 775  
*in* vasculitis, 763-764  
**Keratoconjunctivitis sicca**, in rheumatoid arthritis, 773  
**Kidney**  
 biopsy of, in idiopathic rapidly progressive glomerulonephritis, 708  
 disorders of. *See also* Glomerulonephritis.  
 in antiphospholipid syndrome, 514-516  
 monitoring of, 540  
 prognosis in, 665  
 in Churg-Strauss syndrome, 704-705  
 in Henoch-Schönlein purpura, 693  
 in microscopic polyangiitis, 706  
 in Wegener's granulomatosis, 698-700, 882  
 transplantation of, in Wegener's granulomatosis, 699-700  
 vasculitis of, 707-708  
 cryoglobulinemic, 710  
  
**LA.** *See* Lupus anticoagulant.  
**Lactation**, bone mineral density in, 113-114  
**Laser therapy**, for subglottic stenosis, in Wegener's granulomatosis, 700  
**Late endosomes**, endothelial, antiphospholipid antibody interactions with, 597  
**Leflunomide**  
 for rheumatoid arthritis, 410  
 methotrexate with, 421

for Wegener's granulomatosis, 875  
 Left ventricular assist devices, thrombosis with, antiphospholipid antibodies and, 620-621  
 Lenercept, for rheumatoid arthritis, 436-437  
 Leukemia, in rheumatoid arthritis, 288-290  
 Leukocytoclastic angiitis, cutaneous, 741  
 Leukocytoclastic vasculitis, immune complexes in, 834  
 Leukotrienes, inhibitors of, vasculitis due to, 852  
 Lifestyle changes, in osteoporosis prevention, 15, 36-37, 180  
 Lipids, protein interactions with, in coagulation cascade, 576-577  
 Lipoprotein profile, in rheumatoid arthritis, 285-288  
 Livedo reticularis, in antiphospholipid syndrome, 511  
 Liver dysfunction of, in bone marrow transplantation, 625  
 transplantation of, antiphospholipid antibodies and, 619-620  
 Lumbar puncture, in central nervous system vasculitis, 715-716  
 Lumbosacral plexus, vasculitis affecting, 756, 758  
 Lung antiphospholipid syndrome manifestations in, 516-517, 530-531, 664-665  
 hemorrhage of, in microscopic polyangiitis, 706  
 polyarteritis nodosa effects on, 678  
 Wegener's granulomatosis manifestations in, 700  
 Lupus anticoagulant in antiphospholipid syndrome, 501  
 prognosis and, 662-663  
 in transplantation  
     bone marrow, 623  
     heart, 621-622  
     kidney, 613-614, 617  
     tests for, 536, 552-553  
 Lymphoid organogenesis, in rheumatoid arthritis pathogenesis, 323-326  
 Lymphoma, in rheumatoid arthritis, 288-290  
 Lymphoproliferative disorders, in rheumatoid arthritis, 288-290  
 etanercept-induced, 435  
 infliximab-induced, 431  
 Macrophages, anti-neutrophil cytoplasmic antibodies proinflammatory effects on, 822-823, 896-897  
 Magnetic resonance imaging in central nervous system vasculitis, 715-717  
     in rheumatoid arthritis, 374-375  
 Major histocompatibility complex antagonists of, in rheumatoid arthritis, 453-454  
     in rheumatoid arthritis susceptibility, 305-315  
 Markers, of bone turnover. *See* Bone turnover of, biochemical markers for  
 Matrix cellular proteins, in rheumatoid arthritis pathogenesis, 322-323  
 Medroxyprogesterone, for osteoporosis, 151  
 Men, osteoporosis in, 19-47  
     definition of, 19-20  
     evaluation of, 35-36  
     fractures in  
         epidemiology of, 22-25  
         risk factors for, 27-35  
         versus women, 25-27  
     prevalence of, 20-22  
     prevention of, 34-35  
     treatment of, 33-39, 224-226  
 Metalloproteinases, inhibitors of, for rheumatoid arthritis, 363-364, 466-467  
 Metastasis, to bone, bone turnover markers in, 65-70  
 Methamphetamine, vasculitis due to, 852  
 Methotrexate  
     for rheumatoid arthritis  
         carcinogenic effects of, 288-289  
         cardiovascular effects of, 287  
         early, 406-410  
         immunosuppressive effects of, 290-292  
     in combination, tumor necrosis factor-a blockade, 437-438  
     in combinations, 415-426  
         biologic agents, 422  
         corticosteroids, 422-423  
         cyclosporine, 420  
         etanercept, 422, 433-434  
         hydroxychloroquine, 418, 420-421  
         infliximab, 422, 429-430  
         leflunomide, 421  
         sulfasalazine, 417-418, 420-421  
         triple, 420-421  
         tumor necrosis factor-a blockade, 422  
     suboptimal response to, 419-420  
 for Wegener's granulomatosis, 869-873  
 Microscopic polyangiitis  
     anti-endothelial cell antibody antigens in, 842  
     anti-neutrophil cytoplasmic antibodies in, 800, 836, 842, 888-889  
     antibodies in, 707  
     epidemiology of, 734-737  
     kidney involvement in, 706  
     prognosis for, 705-706  
     pulmonary hemorrhage in, 706

Microscopic polyangiitis (*Continued*)  
 versus Henoch-Schönlein purpura, 692  
 vessels affected by, 705-706

Migraine, anticardiolipin antibodies and, 508-509

Minocycline, for rheumatoid arthritis, 423, 466-467

Mitogen-activated protein kinases in rheumatoid arthritis pathogenesis, 361, 438  
 inhibitors of, for rheumatoid arthritis, 462-463

Molecular mimicry, in antiphospholipid antibody induction, 556-559

Monoclonal antibodies, for rheumatoid arthritis  
 adhesion molecule, 463-464  
 CD4 antigen, 447-450  
 complement, 465  
 tumor necrosis factor- $\alpha$ . *See also* Infliximab.  
 human and humanized, 435-436  
 polyethylene glycolated, 436

Monocytes, anti-neutrophil cytoplasmic antibodies proinflammatory effects on, 822-823, 889, 894, 896-897

Mononeuritis multiplex  
 in polyarteritis nodosa, 679  
 in vasculitis, 754-755

Multiple myeloma  
 bone turnover markers in, 67-69  
 in rheumatoid arthritis, 288-290

Multiple sclerosis, versus antiphospholipid syndrome, 509-510

Muscles  
 biopsy of, in vasculitic neuropathy, 754, 756  
 glucocorticoid effects on, 240-241

Mutation, somatic, in rheumatoid arthritis, 357-360

Mycophenolate mofetil, for Wegener's granulomatosis, 875

Myeloma, multiple, bone turnover markers in, 67-69

Myelopathy, transverse, in antiphospholipid syndrome, 665

Myeloperoxidase  
 anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, myeloperoxidase-directed.  
 in endothelial damage, 891-892

Myocardial infarction, in rheumatoid arthritis, 285

Myocardial ischemia, in antiphospholipid syndrome, 665

Myocardium, Churg-Strauss syndrome effects on, 703

Nailfold infarction, in rheumatoid vasculitis, 724

Necrosis, of bone, glucocorticoid-induced, 239-240

Necrotizing scleritis, in Wegener's granulomatosis, 762

Neovascularization, inhibitors of, for rheumatoid arthritis, 383, 463-464

Nephropathy, in antiphospholipid syndrome, 514-516, 540, 665

Nerve(s)  
 biopsy of, in vasculitic neuropathy, 754, 756  
 vascular organization of, 751-752

Nerve conduction studies  
 in Churg-Strauss syndrome, 705  
 in vasculitis, 755

Neuritis, optic, in vasculitis, 766

Neurologic disorders  
 in antiphospholipid syndrome, 507-511, 665  
 in Behcet's disease, 719-721  
 in central nervous system vasculitis, 715-719

Neuropathy  
 in Churg-Strauss syndrome, 703  
 in giant cell arteritis, 776, 784-787  
 in polyarteritis nodosa, 679  
 optic, in vasculitis, 766, 776, 784-787  
 vasculitic, 751-760  
 anatomic considerations in, 751-752  
 causes of, 751  
 clinical features of, 754-755  
 histology of, 752-754  
 in diabetes mellitus, 756-757  
 in hepatitis, 757-758  
 of peripheral nerves, 756-758  
 treatment of, 758

Neutropenia, in Wegener's granulomatosis, 697, 879

Neutrophil(s), anti-neutrophil cytoplasmic antibody interactions with adhesion of, 890  
 endothelial injury in, 890-892  
 fate of, 892-893  
 in early lesions, 888-889  
 in late lesions, 889  
 priming of, 889-890  
 proinflammatory effects of, 817-820

Nitric oxide, in endothelial damage, 891-892

Nodule(s)  
 in scleritis, 762  
 rheumatoid, in Churg-Strauss syndrome, 702-703

Nonsteroidal anti-inflammatory drugs, for rheumatoid arthritis  
 cardiovascular effects of, 287  
 gastrointestinal effects of, 293, 295-296

Nose, Wegener's granulomatosis manifestations in, 879-880

Nuclear factor- $\kappa$ B, inhibitors of, for rheumatoid arthritis, 362-363, 383, 463

Ocular ischemic syndrome, in giant cell arteritis, 790

Ocular manifestations, of vasculitis, 761-779
 

- in Behcet's disease, 770-772
- in Churg-Strauss syndrome, 769-770
- in Cogan's syndrome, 714-715, 775
- in connective tissue disorders, 772-773
- in giant cell arteritis, 775-777
- in polyarteritis nodosa, 773-774
- in Takayasu's arteritis, 774-775
- in Wegener's granulomatosis, 768-769
- ischemic optic neuropathy, 766
- keratitis, 763-764
- neuro-ophthalmologic, 766-767
- ophthalmoplegia, 766-767
- optic neuritis, 766
- orbital, 767, 881-882
- retinal. *See* Retinopathy, in vasculitis.
- scleritis, 761-763
- uveitis, 764-765

Ophthalmoplegia, in vasculitis, 766-767

Optic neuritis, in vasculitis, 766

Optic neuropathy, in vasculitis, 766

Oral contraceptives, rheumatoid arthritis and, 277

Orbital manifestations, of vasculitis, 767
 

- giant cell arteritis, 790-791
- Wegener's granulomatosis, 768-769, 881-882

Osteoarthritis, osteoporosis and, 145

Osteocalcin, as marker for bone formation, 51-52

Osteoclasts, glucocorticoid effects on, 237-238

Osteolysis, metastatic, bone turnover markers in, 65-70

Osteonecrosis, glucocorticoid-induced, 239-240

Osteoporosis
 

- alcohol use and, 31
- bone turnover markers in, 49-80, 166, 191
- calcium and. *See* Calcium, osteoporosis and.
- clinical features of, glucocorticoid-induced, 235-236
- definition of, 1-2, 165-166
- in men, 19-20
- densitometry in. *See* Densitometry.
- economic impact of, 3
- environmental factors in, 10-12
- epidemiology of, 1-18
  - early environmental influences, 10-12
  - fractures, 2-10
- genetic, 10
- glucocorticoid-induced, 236-237
- in men, 20-22
- morbidity, 13-14
- mortality, 12-13
- ethnic factors in, 9-10, 21-22
- evaluation of
  - biochemical markers in, 57-59
  - glucocorticoid-induced, 240-241
  - in men, 35-36
- fractures in. *See* Fractures, in osteoporosis.
- genetic factors in, 10
- glucocorticoid-induced. *See* Corticosteroids, osteoporosis due to.
- in men, 19-47, 224-226
- in nutritional deficiencies, 101-103
- in rheumatic disease, 164-165
- in rheumatoid arthritis. *See* Rheumatoid arthritis, osteoporosis in.
- latency of, 164
- nonskeletal consequences of, 255-262
  - psychologic, 256-259
  - social, 259-260
- pathophysiology of, 163
  - glucocorticoid-induced, 237-240
- prevalence of, in men, 20-22
- prevention and treatment of, 14-15, 163-185
  - anabolic agents in, 215-233, 246-247
  - bisphosphonates in. *See* Bisphosphonates, for osteoporosis.
  - calcitonin in. *See* Calcitonin.
  - calcium in. *See* Calcium, osteoporosis and.
  - clinical trials of, 178-180
  - combined antiresorptive agents in, 175-176
  - dietary supplementation in, 180-181.
    - See also* Calcium; Vitamin D.
  - estrogens in. *See* Estrogens, for osteoporosis.
  - exercise in, 31-32, 131-141
  - fluoride in, 38, 246-247
  - fracture rate after, 177-180
  - glucocorticoid-induced, 150, 192, 226-228, 879
  - growth hormone in, 217-221
  - in men, 33-39, 224-226
  - indications for, 165-166
  - insulin-like growth factor 1 in, 221-222
  - lifestyle changes in, 15, 36-37, 180
  - methods for, 166-167
  - need for, 163-166
  - parathyroid hormone in, 222-231, 247-248
  - progesterone in, 243-244
  - safety issues in, 228-229
  - selective estrogen receptor modulators in, 151-152, 169-175, 178

Osteoporosis (Continued)  
 testosterone in, 244  
 vitamin D in. *See* Vitamin D, osteoporosis and.  
 psychologic impact of, 256-259  
 risk factors for, in men, 27-35  
 senile (type II), vitamin D in, 123  
 smoking and, 31  
 social impact of, 259-260  
 treatment of. *See* Osteoporosis, prevention and treatment of.  
 vitamin D and. *See* Vitamin D, osteoporosis and.

Osteoprotegerin, in rheumatoid arthritis pathogenesis, 326

Oxygen free radicals, in endothelial damage, 891

**p38 protein**, in rheumatoid arthritis pathogenesis, 361

**p53 tumor suppressor gene**, mutations of, in rheumatoid arthritis, 357-360

Page's disease of bone, bone turnover markers in, 63

**Pain**  
 abdominal, in Henoch-Schönlein purpura, 693  
 back, in Takayasu's arteritis, 710  
 bone, calcitonin effects on, 192-193  
 ocular, in scleritis, 762

Pamidronate, for osteoporosis, 202, 207  
 glucocorticoid-induced, 245  
 side effects of, 200-201

Panuveitis, in vasculitis, 764-765

Paraproteinemia, immunoglobulin A, in Henoch-Schönlein purpura, 692-693

Parathyroid hormone  
 excess of  
 bone turnover markers in, 62-64  
 senile osteoporosis in, 123  
 in calcium metabolism, 117  
 in osteoporosis, 222-231, 247-248  
 levels of, glucocorticoid effects on, 239

Pediatric patients  
 bone densitometry in, 99  
 calcium supplementation in, 112-113  
 physical activity in, bone status and, 133-135

Pelvic fractures, in osteoporosis, epidemiology of, 6

Pentamidine, for *Pneumocystis carinii* prophylaxis, in Wegener's granulomatosis, 878

Peptic ulcer disease, in rheumatoid arthritis, 296, 397

Peripheral nerves, vascular organization of, 751-752

Peripheral ulcerative keratitis, in vasculitis, 763-764

Phospholipids  
 antibodies to. *See* Antiphospholipid antibodies; Antiphospholipid (Hughes) syndrome.  
 protein interactions with, in coagulation cascade, 576-577

Plasmapheresis  
 for antiphospholipid syndrome, 635  
 for Wegener's granulomatosis, 875-876

Platelets, in coagulation cascade, 576

*Pneumocystis carinii* pneumonia, prophylaxis for, in Wegener's granulomatosis, 697, 877-878

Polyangiitis, microscopic. *See* Microscopic polyangiitis.

Polyarteritis nodosa  
 atrophie blanche in, 681-682  
 epidemiology of, 734-737  
 gastrocnemius muscle biopsy in, 680  
 lung involvement in, 678  
 mononeuritis multiplex in, 679  
 ocular manifestations of, 773-774  
 sural nerve biopsy in, 680  
 treatment of, 678  
 venous sparing in, 681  
 visceral abdominal angiography in, 680-681

Polyethylene glycol  
 in monoclonal antibody modification, for rheumatoid arthritis treatment, 436

in soluble tumor necrosis factor receptor type 1 modification, for rheumatoid arthritis treatment, 437

Polymyalgia rheumatica, 688-689

Polymyositis, vasculitis in, 743

Pre-eclampsia, in antiphospholipid syndrome, 646, 649

Prednisolone  
 for antiphospholipid syndrome, in pregnancy, 650  
 for rheumatoid arthritis, 390-392  
 early, 407-410  
 in combinations, 417-418, 423  
 radiologic progression and, 393-394  
 withdrawal from, 400

Prednisone  
 for Churg-Strauss syndrome, 769-770  
 for giant cell arteritis, 777  
 for polyarteritis nodosa, 774  
 for polymyalgia rheumatica, 688-689  
 for rheumatoid arthritis, 407  
 osteoporosis induced by, 292-293, 295  
 for scleritis, in vasculitis, 763  
 for uveitis, in vasculitis, 765  
 for Wegener's granulomatosis, 865  
 methotrexate with, 869-871

Pregnancy  
 bone mineral density in, 113-114  
 in antiphospholipid syndrome, 501, 643-659

antibody tests in, 535, 538-539  
 early failure of, 645  
 effects on pregnancy, 644-648, 664  
 effects on syndrome, 643-644  
 fetal risks in, 646-647, 664  
 late complications of, 645  
 maternal risks in, 645-646  
 morbidity in, 664  
 placental pathology in, 646  
 treatment of, 647-654  
 pharmacologic, 649-653  
 preconception, 647, 649  
 with antibodies alone, 654  
 with previous thrombosis, 653-654  
 with recurrent fetal loss, 654  
 in Takayasu's arteritis, 713

Progesterone, for osteoporosis, 150, 243-244

Programming, of osteoporosis, 11-12

Proptosis, in vasculitis, 767

Protein(s)  
 excess intake of, calcium balance and, 107  
 lipid interactions with, in coagulation cascade, 576-577

Protein C, activated, in coagulation, 578-580, 582

Protein S  
 deficiency in, in antiphospholipid syndrome, 536  
 resistance to, in antiphospholipid syndrome, 536, 538

Proteinase(s), in endothelial damage, 891

Proteinase 3, anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, proteinase 3-directed.

Prothrombin  
 activation fragments of, in antiphospholipid syndrome, 537  
 in coagulation, antiphospholipid antibodies and, 578, 581-582

Proto-oncogenes, activation of, in rheumatoid arthritis, 356-357

Psychologic impact, of osteoporosis, 256-259

Puberty, bone development in, men versus women, 26

Pulmonary embolism, in antiphospholipid syndrome, 516, 664-665  
 treatment of, 633-634

Pulmonary hypertension, in antiphospholipid syndrome, 516-517, 530-531, 664-665

Pulmonary-renal syndromes, anti-neutrophil cytoplasmic antibodies in, 807-808

Pulse, loss of, in Takayasu's arteritis, 711-712

Pupillary disturbances, in giant cell arteritis, 790

Purpura  
*Henoch-Schönlein. See* Henoch-Schönlein purpura.  
 in cryoglobulinemic vasculitis, 708-709  
 in drug-induced vasculitis, 854

Raloxifene, for osteoporosis, 170-175, 178  
 estrogens with, 151

Rash, maculopapular, in drug-induced vasculitis, 854

Reactive oxygen species, in endothelial damage, 891

Remodeling transient, bone, 102-103

Renal vessels, thrombosis of, in antiphospholipid syndrome, 515

Respiratory burst, anti-neutrophil cytoplasmic antibodies effects on, 819

Retinopathy  
 in antiphospholipid syndrome, 510-511  
 in Behcet's disease, 771-772  
 in giant cell arteritis, 776-777, 782-784  
 in polyarteritis nodosa, 774  
 in systemic lupus erythematosus, 773  
 in Takayasu's arteritis, 774-775  
 in vasculitis, 765-766

Rheumatoid arthritis, 317-354  
 anti-neutrophil cytoplasmic antibodies in, 801  
 cardiovascular disease in, 285-288, 294  
 comorbidity in, 283-284  
 early, treatment of, 405-414, 417-419  
 economic issues in, 283  
 endothelial dysfunction in, 897  
 epidemiology of, 269-281  
 incidence, 271-274  
 mortality, 274-275  
 prevalence, 274  
 gastrointestinal disease in, 293, 295-296  
 human leukocyte antigens in, 305-315  
 infections in. *See* Infections, in rheumatoid arthritis.  
 malignancy in, 288-290, 294, 431  
 mortality in, 274-275, 283-284  
 corticosteroid effects on, 395-396  
 ocular manifestations of, 772  
 osteoporosis in, 146, 164-165, 292-293, 295, 398  
 bone turnover markers in, 72  
 parathyroid hormone in, 229-230

pathogenesis of  
 B lymphocytes in, 335-353, 465  
 clinical aspects of, 373-387  
 immune function functional analysis, 376  
 synovitis characterization, 374-376  
 treatments developed from, 379-383  
 trials, 377-379  
 education and, 278

Rheumatoid arthritis (Continued)

- estrogens in, 277
- genetic factors in, 275-276, 305-315
- infections in, 276-277
- smoking in, 277
- synoviocytes in, 355-371
- T lymphocytes in. *See* T lymphocytes, in rheumatoid arthritis pathogenesis.
- tumor necrosis factor- $\alpha$  in, 319-320, 322, 378-383, 427-428
- radiology in, corticosteroid effects on, 393-394
- risk factors for, 275-278
- treatment of
  - aggressive, 406-412
  - B lymphocyte-directed, 346
  - biological agents in. *See* Biologic agents, for rheumatoid arthritis; specific agents.
  - cardiovascular effects of, 287-288
  - corticosteroids in. *See* Corticosteroids, for rheumatoid arthritis.
  - disease-modifying antirheumatic drugs in, 415-426
  - gene therapy in, 467
  - human leukocyte antigen considerations in, 305-315
  - in early disease, 405-414, 417-419
  - pathogenesis information from, 377-379
  - tumor necrosis factor- $\alpha$  blockade in. *See* Tumor necrosis factor- $\alpha$ , blockade of.
  - window of opportunity for, 411-412
- vasculitis in, 723-724, 742

Rheumatoid factor, in rheumatoid arthritis, 335-336, 340-341

Rheumatoid nodules, in Churg-Strauss syndrome, 702-703

Rheumatoid vasculitis, 723-724

Rib fractures, in osteoporosis, in men, 25

Rickets, bone disease in, 120-121

Risedronate, for osteoporosis, 168-169, 178, 205-206

glucocorticoid-induced, 245

Saddle nose deformity, in Wegener's granulomatosis, 880

Sagittal venous sinus thrombosis, in antiphospholipid syndrome, 508

Sarcoidosis, vasculitis related to, 743

Scleritis, in vasculitis, 761-763
 

- in rheumatoid arthritis, 773
- in Wegener's granulomatosis, 768

Sclerokeratitis, in vasculitis, 763-764

Scott syndrome, 577

Seizures, in antiphospholipid syndrome, 510

Selective estrogen receptor modulators, for osteoporosis, 169-175, 178

estrogens with, 151-152

Serine proteinase 3, anti-neutrophil cytoplasmic antibodies directed to. *See* Anti-neutrophil cytoplasmic antibodies, proteinase 3-directed.

Sex hormones. *See also* specific hormones.
 

- in osteoporosis, fracture risk and, 27-31

Shwartzman reaction, in vasculitis, 834

Sialoprotein, bone, as marker for bone resorption, 53-54

Signal transduction, abnormalities of, in rheumatoid arthritis, 360-363

Single energy densitometry, 82

Sjögren's syndrome
 

- ocular manifestations of, 773
- osteoporosis in, parathyroid hormone in, 229-230

Skin disorders
 

- in antiphospholipid syndrome, 511-512
- in drug-induced vasculitis, 854
- in Henoch-Schönlein purpura, 689-693
- in Takayasu's arteritis, 713
- leukocytoclastic angiitis, 741

Smoking
 

- Buerger's disease in, 722
- osteoporosis in, 31
- rheumatoid arthritis in, 277

Social impact, of osteoporosis, 259-260

Sodium, intake of, calcium balance and, 106-107

Somatic mutations, in rheumatoid arthritis, 357-360

Spinal cord disorders, in antiphospholipid syndrome, 665

Spine
 

- densitometry of, 95-96
- in change monitoring, 95
- morphometric measurements in, 97
- quantitative computed tomography in, 85, 88
- fractures of. *See* Vertebral fractures.

Splinter hemorrhages, in Buerger's disease, 722

Staphylococcal acid phosphatase, vasculitis related to, 842-843

Staphylococcus aureus, antigens to, vasculitis related to, 842-843, 896

Strength, glucocorticoid effects on, 240-241

Streptococcus pneumoniae infections, antiphospholipid antibody induction in, 558

Stroke
 

- in antiphospholipid syndrome, 508-509
- in pregnancy, 646
- prevention of, 539-540
- treatment of, 634
- versus central nervous system vasculitis, 716

Stromelysin, in rheumatoid arthritis pathogenesis, 363

Subglottic stenosis, in Wegener's granulomatosis, 700, 880

Sulfasalazine, for rheumatoid arthritis early, 406-408, 410  
in combinations, 417-418, 420-421

Sural nerve, biopsy of  
in Churg-Strauss syndrome, 705  
in polyarteritis nodosa, 680

Swimmers, bone status of, 137

Synoviocytes, in rheumatoid arthritis, 355-371  
matrix-modifying enzymes in, 322-323, 363-366  
partial transformation of, 355-360  
signal transduction in, 360-363

Synovitis, in rheumatoid arthritis, pathogenesis of. *See* Rheumatoid arthritis, pathogenesis of.

Synovium  
biopsy of, in rheumatoid arthritis, 374-376  
lymphocytic infiltration of, in rheumatoid arthritis, 343-345

Syphilis, antiphospholipid antibodies in, 551-552

Systemic lupus erythematosus  
anti-neutrophil cytoplasmic antibodies in, 801  
antiphospholipid antibodies in  
atherosclerosis development and, 603-604  
prognosis in, 662  
tests for, 529

endothelial dysfunction in, 897

etanercept-induced, 435

immune complexes in, 834

infliximab-induced, 430-431

kidney transplantation in, 616-617

ocular manifestations of, 772-773

vasculitis in, epidemiology of, 742

Systemic sclerosis, vasculitis in, epidemiology of, 742-743

T lymphocytes  
in endothelial damage, in vasculitis, 895-896

in rheumatoid arthritis pathogenesis, 317-334, 377-379, 381-383  
apoptosis of, 465-466  
as treatment targets, 446-454  
costimulatory molecules in, 320-322  
cytokines in, 319-320  
effector mechanisms and, 326-328  
function regulation and, 317-323  
human leukocyte antigen DR4 in, 305-315

lymphoid organogenesis and, 323-326  
matricellular proteins in, 322-323  
migration of, 318-319

receptor for, in rheumatoid arthritis vaccines, 450-451

T-score, in densitometry, 92-94

Tacrolimus  
for Wegener's granulomatosis, 876

neurotoxicity of, 720

Takayasu's arteritis  
angiography in, 711, 713  
back pain in, 710  
bruit in, 710-711

C-reactive protein in, 711

cardiomyopathy in, 713

carotid bypass graft for, 714

epidemiology of, 732-734

erythrocyte sedimentation rate in, 711

genetic factors in, 732-733

ocular manifestations of, 774-775

pregnancy in, 713

pulse loss in, 711-712

skin lesions in, 713

treatment of, corticosteroids in, 714

Tamoxifen, for osteoporosis, 175

Tartrate-resistant acid phosphatase, as marker for bone resorption, 53-55

TdT protein, abnormalities of, in rheumatoid arthritis, 345-346

Telomerase, in rheumatoid arthritis, 357

Temporal arteritis. *See* Giant cell (temporal) arteritis.

Temporal artery, biopsy of, 683-687

Testosterone, for osteoporosis  
estrogens with, 150-151  
fracture risk and, 28-30  
glucocorticoid-induced, 244  
in men, 38

Tetracyclines, for rheumatoid arthritis, 466-467

Throat, Wegener's granulomatosis  
manifestations in, 879-880

Thrombin, in coagulation, antiphospholipid antibodies and, 578

Thrombocytopenia, in antiphospholipid syndrome, 517  
prognosis and, 664  
treatment of, 639

Thrombolytic therapy, for antiphospholipid syndrome, 634

Thrombomodulin, in coagulation, antiphospholipid antibodies and, 579-580, 582

Thrombophlebitis  
in Behcet's disease, 719  
in Buerger's disease, 721

Thrombosis  
in antiphospholipid syndrome, 501  
acute, treatment of, 633-634  
cardiac, 512-514, 554

Thrombosis (Continued)

- catastrophic, 634–635, 666
- central nervous system, 507–511, 539–540, 665
- coagulation cascade and, 573–586
- cutaneous, 511–512
- endothelial interactions in, 587–602
- hematologic, 517–518
- kidney, 514–516, 665
- predictive tests for. *See* Antiphospholipid antibodies, tests for.
- pulmonary, 516–517, 664–665
- scope of, 633
- transplantation and. *See* Transplantation.
- treatment of, 633–642
  - acute, 633–634
  - catastrophic, 634–635
  - chronic, 635–640
- in vasculitis, pathophysiology of, 894

Thrombospondin, receptors for, in rheumatoid arthritis pathogenesis, 323

Tibial fractures in osteoporosis, 323

Tissue factor, in coagulation, antiphospholipid antibodies and, 577–578

Toxemia, of pregnancy, in antiphospholipid syndrome, 646

Trachea, dilatation of, in Wegener's granulomatosis, 881

Tracheostomy, in Wegener's granulomatosis, 881

Transcription factors, in rheumatoid arthritis pathogenesis, 360–363

Transplantation

- antiphospholipid antibodies and, 611–631
  - apoptosis in, 626–627
  - bone marrow, 623–626
  - fluorescence-activated cell sorter cross-matching in, 622–623
  - heart, 620–621
  - historical perspective of, 611–613
  - kidney, 516, 613–619
  - liver, 619–620
  - vascular grafts, 621–622
  - with left ventricular assist systems, 620–621
- kidney, in Wegener's granulomatosis, 699–700

Transverse myelopathy, in antiphospholipid syndrome, 665

Trimethoprim-sulfamethoxazole for Wegener's granulomatosis, 873–874

prophylactic, for Wegener's granulomatosis, 697

Tuberculosis, in rheumatoid arthritis

- corticosteroids and, 397
- tumor necrosis factor- $\alpha$  blocker-related, 438

Tumor necrosis factor- $\alpha$

- chemical structure of, 427–428
- in rheumatoid arthritis pathogenesis, 319–320, 327, 378–383, 427–428
- inhibitors of
  - for rheumatoid arthritis, 380–381, 410, 427–443
  - biology of, 427–428
  - combination, 437–438
  - current agents for, 428–435. *See also* Etanercept; Infliximab.
  - future agents for, 435–438
  - infection surveillance in, 438
  - methotrexate with, 422
  - monoclonal antibodies in, 435–436
  - pathogenesis and, 428
  - small molecule type, 438
  - soluble receptors in, 436–437
  - unresolved issues in, 439–440
  - for Wegener's granulomatosis, 877
- soluble form of, 427

Tumor suppressor genes, mutations of, in rheumatoid arthritis, 357–360

Ulcer(s)

- corneal, in giant cell arteritis, 792
- in Buerger's disease, 721–722
- lower extremity, in polyarteritis nodosa, 681
- skin, in antiphospholipid syndrome, 511–512

Ultrasonography, quantitative, in bone density measurement, 88–90

Urine, calcium excretion in, osteoporosis in, 106

Urticarial vasculitis, 723

Uveitis, in vasculitis, 764–765, 770–772

Vaccines

- T-cell receptor, in rheumatoid arthritis, 450–451
- vasculitis due to, 850, 852

Valvular heart disease, in antiphospholipid syndrome, 512–513

Vascular bypass grafts, antiphospholipid antibodies and, 621–622

Vasculitis. *See also* Arteritis; specific diseases.

- anti-neutrophil cytoplasmic antibodies in
  - clinical use of, 799–813
  - leukocyte-endothelial interactions in, 887–903
  - pathogenic significance of, 815–832, 833–848
- central nervous system, 715–720
- cryoglobulinemic, 708–710

epidemiology of, 741  
immune complexes in, 834  
drug-induced, 849-862  
anti-neutrophil cytoplasmic autoantibody-positive, 853-854  
causal agents in, 849-853  
clinical features of, 854  
diagnosis of, 854-856  
epidemiology of, 735  
regulatory issues in, 850  
research on, 857  
treatment of, 856-857  
vaccines and, 850, 852  
epidemiology of, 729-749  
primary, 730-741  
secondary, 742-743  
etiology of, 897-898  
historical background of, 677-678  
hypersensitivity. *See also* Vasculitis, drug-induced.  
epidemiology of, 741  
in Behcet's disease, 719-721, 743  
in Buerger's disease, 721-723  
in Churg-Strauss syndrome, 702-705  
in dermatomyositis, 743  
in Henoch-Schönlein purpura. *See* Henoch-Schönlein purpura.  
in microscopic polyangiitis. *See* Microscopic polyangiitis.  
in polymyositis, 743  
in rheumatoid arthritis, 285, 742  
in systemic lupus erythematosus, epidemiology of, 742  
in Wegener's granulomatosis. *See* Wegener's granulomatosis.  
leukocytoclastic, immune complexes in, 834  
myths about. *See* Vasculitis, pearls and myths about.  
neuropathy in, 751-760  
nonsystemic, 756  
ocular manifestations of. *See* Ocular manifestations, of vasculitis; Giant cell (temporal) arteritis, visual manifestations of.  
pathogenesis of, anti-neutrophil cytoplasmic antibodies in. *See* Anti-neutrophil cytoplasmic antibodies, pathogenicity of.  
pearls and myths about, 677-728  
Behcet's disease, 719-721  
Buerger's disease, 721-723  
central nervous system, 715-719  
Churg-Strauss syndrome, 702-705  
Cogan's syndrome, 714-715  
cryoglobulinemic, 708-710  
giant cell arteritis, 681, 683-688  
Henoch-Schönlein purpura, 689-694  
idiopathic rapidly progressive glomerulonephritis, 707-708

microscopic polyangiitis, 705-707  
polyarteritis nodosa, 678-682  
polymyalgia rheumatica, 688-689  
rheumatoid, 723-724  
Takayasu's arteritis, 710-714  
urticarial, 723  
Wegener's granulomatosis, 684-702  
renal-limited, 707-708  
retinal. *See* Retinopathy, in vasculitis.  
rheumatoid, 723-724  
urticarial, 723  
Wegener's granulomatosis. *See* Wegener's granulomatosis.  
Vasoactivity, of antiphospholipid antibodies, 596  
Venous thrombosis, in antiphospholipid syndrome, treatment of, 633-634  
Vertebral fractures, in osteoporosis bisphosphonate effects on, 168-169  
calcitonin effects on, 190-191  
detection of, 166  
epidemiology of, 5-6, 24-25  
in men, 24-25, 32  
morbidity in, 14  
mortality in, 13  
prediction of, densitometry in, 94  
risk of, in estrogen deficiency, 144-145  
treatment effects on, 177-180  
with other fractures, 6-7  
Viral infections, antiphospholipid antibody induction in, 555-559  
Visceral abdominal angiography, in polyarteritis nodosa, 680-681  
Vision, loss of  
in antiphospholipid syndrome, 510-511  
in giant cell arteritis, 781  
Visual field defects, in giant cell arteritis, 787-789  
Visual hallucinations, in giant cell arteritis, 789  
Vitamin D, osteoporosis and, 117-125  
deficiency, 120-121  
dietary guidelines for, 120  
food sources of, 120  
forms of, 117-118  
mechanism of action of, 117-119  
metabolism of, 117-119  
supplementation with, 122-125, 166-167  
in calcitonin therapy, 193  
in glucocorticoid therapy, 242-243, 879  
in men, 37  
toxicity, 122

Warfarin, for antiphospholipid syndrome acute, 633-634  
chronic, 635-640  
in pregnancy, 652  
Wassermann reagent, 551-552

Wegener's granulomatosis  
anti-endothelial cell antibody antigens in, 842  
anti-neutrophil cytoplasmic antibodies in, 836, 839-840, 842-843, 888-889  
monocytes and macrophages and, 822-823  
serologic testing and, 800, 804, 808  
cellular immunity in, 896  
chest radiography in, 695  
epidemiology of, 734-737  
hematuria in, 694-695  
immune complexes in, 838-840  
limited, treatment of, 864  
mortality in, 864  
necrotizing scleritis in, 762  
ocular manifestations of, 767-769  
refractory, versus opportunistic infection, 700-702  
severe, treatment of, 864  
*Staphylococcus aureus* antigens in, 842-843, 896  
treatment of, 694-702, 863-886  
azathioprine in, 872  
biologic agents in, 877  
corticosteroids in, 698-699, 864-865, 869-871  
cyclophosphamide in, 695-697, 865-868, 878-879  
for remission induction, 864-871  
for remission maintenance, 871-874  
goals of, 863  
immune globulin in, 875-876  
in kidney failure, 882  
in nasal problems, 879-880  
in orbital inflammation, 881-882  
in otolaryngologic complications, 879-880  
in subglottic stenosis, 880-881  
kidney transplantation in, 699-700  
leflunomide in, 875  
limited, 864  
methotrexate in, 869-873  
mycophenolate mofetil in, 875  
neutropenia in, 697  
plasmapheresis in, 876  
prophylactic therapies in, 877-879  
severe, 864  
subglottic stenosis in, 700  
surgical, 698, 700  
trimethoprim-sulfamethoxazole in, 873-874  
versus Churg-Strauss syndrome, 702-703  
Weight, osteoporosis risk and, 31  
World Health Organization, osteoporosis criteria for, 20  
Wrist fractures, in osteoporosis, 6, 14

Z-score, in densitometry, 92-93

